1. Pink Sheet
  2. >>Agency Leadership

Gottlieb Wants His US FDA Team To Stay Together After He Departs

 
• By Derrick Gingery

INFOGRAPHIC: Wait time for confirmed commissioner has been trending down.

FDAEntrance_1200x675

Outgoing US FDA Commissioner Scott Gottlieb does not want the agency hierarchy shook up once he departs, preferring "to keep the FDA team intact," he said.

Gottlieb shocked many FDA observers and stakeholders March 5 by announcing that he planned to leave the agency in about...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership

US FDA Requires Opioid Class Labeling Changes Despite Adcomm Advice

 
• By Kate Rawson

Quantitative estimates of the safety risks with opioid pain medication, including the risk of addiction and misuse, must be added to labeling.

US FDA Skips User Fee Increase For More Staff Amid Exodus, Hiring Difficulties

 
• By Derrick Gingery

A calculation used to determine whether the FDA has the staff to handle its workload also was not included in the description of prescription drug user fee calculations.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 
• By Sarah Karlin-Smith

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.